Dental pulp stem cells: State of the art and suggestions for a true translation of research into therapy  by La Noce, Marcella et al.
Review
Dental pulp stem cells: State of the art and
suggestions for a true translation of research
into therapy
Marcella La Noce a, Francesca Paino a, Anna Spina a, Pasqualina Naddeo a,
Roberta Montella a, Vincenzo Desiderio a, Alfredo De Rosa b,
Gianpaolo Papaccio a,*, Virginia Tirino a,*, Luigi Laino c
aDepartment of Experimental Medicine, Second University of Naples, Italy
bDepartment of Odontology and Surgery, Second University of Naples, Italy
cDepartment of Clinical and Experimental Medicine, University of Foggia, Italy
j o u r n a l o f d e n t i s t r y 4 2 ( 2 0 1 4 ) 7 6 1 – 7 6 8
a r t i c l e i n f o
Article history:
Received 22 January 2014
Received in revised form
18 February 2014
Accepted 20 February 2014
Keywords:
Adult stem cells
Bone regeneration
Human grafts
Scaffold
Tissue engineering
Stem cell therapy
a b s t r a c t
Objectives: Stem cells have the ability to rescue and/or repair injured tissue. In humans, it is
possible to isolate different types of stem cells from the body. Among these, dental pulp
stem cells (DPSCs) are relatively easily obtainable and exhibit high plasticity and multipo-
tential capabilities. In particular they represent a gold standard for neural-crest-derived
bone reconstruction in humans and can be used for the repair of body defects in low-risk
autologous therapeutic strategies.
Sources: An electronic search was conducted on PubMed databases and supplemented with
a manual study of relevant references.
Results: All research described in this review highlight that DPSCs are mesenchymal stem
cells that could be used in clinical applications. Unfortunately, very few clinical trials have
been reported. Major obstacles imposed on researchers are hindering the translation of
potentially effective therapies to the clinic. Both researchers and regulatory institutions need
to develop a new approach to this problem, drawing up a new policy for good manufacturing
practice (GMP) procedures. We strongly suggest that only general rules be standardized rather
than everything. Importantly, this would not have an effect on the safety of patients, but may
very well affect the results, which cannot be identical for all patients, due to physiological
diversity in the biology of each patient. Alternatively, it would be important to study the role of
specific molecules that recruit endogenous stem cells for tissue regeneration. In this way, the
clinical use of stem cells could be successfully developed.
Conclusions: DPSCs are mesenchymal stem cells that differentiate into different tissues,
maintain their characteristics after cryopreservation, differentiate into bone-like tissues when
loaded on scaffolds in animal models, and regenerate bone in human grafts. In summary, all
data reported up to now should encourage the development of clinical procedures using DPSCs.
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The stem cell field represents an area of particular interest for
scientific research. The results so far obtained give good
expectations for the use of stem cells in clinical trials. New
therapeutic strategies have been made possible thanks to great
advancements in stem cell biology, with the aim of regenerating
tissues injured by disease.1,2 Based on their ability to rescue
and/or repair injured tissue and partially restore organ function,
multiple types of stem/progenitor cells have been speculated. A
primary goal is to identify how different tissues and organs can
arise from undifferentiated stem cells.
Stemness is the capability of undifferentiated cells to
undergo an indefinite number of replications (self-renewal)
and give rise to specialized cells (differentiation). Therefore,
stem cells differ from other types of cells in the body because
they are capable of sustaining self-renewal, are unspecialized,
and can give rise to differentiated cell types. Differentiation
can be recognized by a change in the morphology of the cell
and by the detection of tissue-specific proteins.3 Stem cells
may remain quiescent (non-dividing) for long periods of time
until they are activated by a physiological need for more cells
to maintain tissues, by disease, or by tissue injury. Thus, the
primary role of adult stem cells is to maintain and repair the
tissue in which they are found. They are thought to reside in
specific areas termed stem cell niches.4 Adult stem cells have
been identified in many organs and tissues, including brain,
bone marrow, peripheral blood, blood vessels, skeletal muscle,
skin, teeth, heart, gut, liver, ovarian epithelium, and testis.5
Among these tissues, dental pulp is considered a rich source of
mesenchymal stem cells suitable for tissue engineering
applications and, for this reason, many studies are performed
with the final aim of obtaining new bone.6–8
Tissue engineering is a multidisciplinary field that com-
bines biology, engineering, and clinical science in order to
generate new tissues and organs. This science involves
different steps, such as the identification of appropriate cells,
the development of scaffolds, and the study of morphogenic
signals required to induce cells to regenerate a tissue or
organ.9 After having discussed the state of the art in the field ofFig. 1 – (A) Explant method by which dental pulp is fragmented i
method by which dental pulp is digested in collagense/dispase 
for expression of stemness markers by flow cytometry.dental pulp stem cells research and their potential use in bone
engineering, here we try to suggest how to overcome the
problems limiting the translationability of research, with the
aim of improving the health of patients.
2. Dental pulp stem cells (DPSCS)
Dental pulp, a soft connective tissue within the dental crown,
is an interesting source of adult stem cells because of the large
amount of cells present and the non invasiveness of the
isolation methods compared to other adult tissue
sources.8,10,11 Dental pulp contains mesenchymal stem cells
defined as dental pulp stem cells (DPSCs). DPSCs are obtained
from human permanent and primary teeth, human wisdom
teeth, human exfoliated deciduous teeth (SHEDs), and apical
papilla.7,12–14 Moreover, DPSCs can be also isolated from
supernumerary teeth, which are generally discarded.15 Other
sources of dental stem cells are the periodontal ligament,
which houses periodontal ligament stem cells (PDLSCs),16 and
the dental follicle, which contains dental follicle progenitor
cells (DFPCs).17,18 DPSCs have been isolated from different
organisms, including humans, mouse, rat, sheep, chimpan-
zee, and pig.19,21–23
DPSCs differentiate into different kinds of cells and
tissues24–28 and their multipotency has been compared to
those of bone marrow stem cells (BMSCs). It has been
demonstrated that proliferation, availability, and cell number
of DPSCs are greater than BMSCs.20
There are two widely used methods for the isolation of
dental pulp stem cells: the explant method (DPSC-OG) and the
enzymatic digestion method of the pulp tissue (DPSC-EZ)
(Fig. 1). The explant method is based on outgrowth of cells
from tissue fragments and subsequent adherence on a plastic
surface.29,30 The second technique consists of sterile surgical
removal of dental pulp, digestion in collagenase/dispase,
characterization, and screening through the use of specific
markers.13 It has been demonstrated that the outgrowth
method allows DPSCs to differentiate into skeletal muscle
fibres.29 Isolation by enzymatic digestion is based on the use of
flow-cytometers with a fluorescent activated cell sorter (FACS)nto pieces and cultured in medium; (B) enzymatic digestion
solution and then the cell suspension obtained is screened
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(complexity and size of cells) and antigenic characteristics.13
Different mesenchymal stem cell markers are used to select
different subsets of DPSCs showing diverse biological beha-
viours.31 Yang and colleagues32 demonstrated that STRO1
identifies a subgroup of DPSCs with odontogenic and
osteogenic properties.32 Another DPSC population is positive
for CD34 and CD117 and negative for CD45.13 This population
has great self-expansion and osteogenic differentiation
capabilities and produces a living autologous fibrous bone
(LAB) tissue in vitro13 and bone tissue when implanted in mice.
Such DPSCs can be expanded for long periods and split for up
to 80 passages while still showing plasticity and the capacity
for nodule and bone chip formation in vitro.13,33 This capability
occurs if cells are not detached from their substrate, avoiding
the loss of cell to cell interactions, fundamental for extracel-
lular matrix secretion.28
Other markers expressed by DPSCs are CD29 and CD4434 as
well as CD73 and CD10535, all markers of mesenchymal
stemness. Despite this, these markers are not used for
isolating DPSCs; however, they are used for characterization.
DPSCs are reported to express also OCT4 and Nanog,
transcriptional factors involved in pluri/multipotency main-
tenance.36 Another technique used to isolate stem cells is
based on the efflux of Hoechst33342 dye. Stem cells are able to
exclude Hoechst dye through the membrane efflux pumps of
ATP-binding cassette transporters, such as ABCG2.37 Iohara
et al. isolated porcine and canine DPSCs by their side
population profile.21,38
Numerous studies have evaluated the multipotency of
DPSCs. Various studies have demonstrated that DPSCs are
able to differentiate into osteoblasts when cultured in
osteogenic medium supplemented with dexamethasone,
beta-glycerophosphate, and ascorbic acid.39,40 However, Laino
and colleagues showed that CD34+CD117+ DPSCs can be
differentiated into osteoblasts with standard medium supple-
mented with 20% FBS and without osteogenic inducers.13
Recently, it has been also demonstrated41 that the specific
suppression of individual histone deacetylases (HDACs) by
RNA interference could enhance osteoblast differentiation,
and that HDAC1 as well as HDAC2 are critical enzymes for
osteoblast differentiation. In particular, treatment of DPSCs
with VPA significantly improves mineralized matrix forma-
tion, enhancing expression of bone glycoproteins, such as
osteopontin and bone sialoprotein—both involved in the
formation of the mineralized matrix—but negatively affecting
the expression of osteocalcin, a late-stage marker of differen-
tiation.41 Different culture conditions have been found to
improve osteogenic lineage differentiation: for example, with
the use of a piastrinic lysate as an alternative to FBS.42
Overall, DPSCs are more suitable than BM-MSCs for
mineralized tissue regeneration.20 Other studies highlighted
the ability of DPSCs to express chondrogenic markers.43,44
DPSC differentiate also into other cell types, including
smooth muscle cells, adipocyte-like cells, and neurons.45,26,46
It was recently demonstrated that DPSCs express proteins
involved in melanogenesis at different points during their
differentiation in vitro, even when they are not stimulated by a
selective differentiating medium for melanocytes, demon-
strating for the first time that DPSCs are capable ofspontaneously differentiating into mature melanocytes47. In
addition, DPSCs are able to form capillary-like structures when
cultured with VEGF.48 It has been demonstrated28 that human
DPSCs synergistically differentiate into osteoblasts and
endothelial cells. Great attention has also been focused on
the ability of DPSCs to differentiate into odontoblast-like cells,
characterized by polarized cell bodies and accumulation of
mineralized nodules.25,49,50
Another fundamental aspect investigated is the mainte-
nance of cell stemness. Human DPSCs exposed to optimal
concentrations of small molecules (Pluripotin (SC1), 6-bro-
moindirubin-3-oxime, and rapamycin) showed increased
expression of STRO-1, NANOG, OCT4, and SOX2, but dimin-
ished differentiation into odonto/osteogenic, adipogenic, and
neurogenic lineages in vitro.51
Another aspect to be considered is the ability of DPSCs to
maintain their characteristics after cryopreservation for years.
Osteoblasts differentiated from DPSCs, as well as DPSCs
themselves, are still capable of re-starting proliferation,
differentiation, and producing a mineralized matrix.33,52
3. DPSCS and perspectives for tissue
engineering
In recent years, studies have focused on the possible
application of stem cells and tissue engineering to mend
and regenerate body structures.6,8,33,53 This new idea of
therapy, known as regenerative medicine, may be ready for
clinical applications in the future. It has been hypothesized
that stem cells could play a key role in future medical
treatments because they can be readily grown and induced to
differentiate into different cell types in culture.53 The general
aim of tissue engineering is to restore the vitality and function
of diseased and traumatized tissue. Several approaches,
already studied in oral and maxillofacial surgery, can be used
for bone repair, including: (1) autologous grafts using cells and
growth factors with osteogenic properties54; (2) allogenic and
xenogenic grafts, using portions of bone with osteoinductive
properties from other humans or animals55; (3) osteoinductive
biomaterials that serve as carriers for osteogenic growth
factors56; (4) synthetic materials able to regenerate bone with
or without partial resorption.
The creation of a medical device for use in oral tissue
engineering requires accessible sources of cells and biocom-
patible materials that can also carry signalling molecules.
Many strategies used in tissue engineering depend on the use
of scaffolds, and those for bone regeneration are highly
sophisticated structures. These scaffolds are designed to
support the adhesion, cell spreading, and deposition of new
tissue, avoiding the need for artificial implants. An ideal
scaffold should have specific chemical and physical char-
acteristics: the main properties are biocompatibility, to
optimize tissue regeneration without side effects from the
immune response; biodegradability, so as to be absorbed
simultaneously with cell growth; and specific mechanical
properties, so as to be stable and to resist the in vivo stresses.
Numerous studies have been performed using DPSCs
loaded onto scaffolds of collagen sponges (Fig. 2), hydroxyap-
atite (HA), chitosan, biocoral, or PLGA.57,32,58–64 Yang and
Fig. 2 – Diagram of bone tissue engineering from dental pulp stem cells.
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collagen complex formed a dentine-pulp complex.57 The same
group reported also that DPSCs loaded on HA/TCP disks
formed bone.32 In contrast, Zhang and colleagues58 reported
that DPSCs loaded onto spongeous collagen and transplanted
into mice were not able to form hard tissues. They hypothe-
sized that the micro-structure and characteristics of the
collagen might be the main cause of the negative result.58
In this context, a key aspect is the three-dimensional
macrostructure that mimics the physiological functions of
extracellular matrix (ECM). Porosity is important for good bone
growth; pore size must be between 100 and 400 mm59, and they
should be open and interlinked to enable diffusion, penetration,
adherence, and proliferation of cells.60 The presence of surface
microcavities leads to a greater osteogenic response of stem
cell. In fact, N-methyl-pyrrolidone treatment of PLGA scaffolds
was demonstrated to improve cell adhesion and polarity,
mainly by increasing the presence of microcavities on the
scaffold.61 Furthermore, the cells in this microenvironment
released larger amounts of BMP-2 and VEGF in the culture
medium and increased alkaline phosphatase activity.61
An important factor in the construction of the scaffold is
the material used to produce it. A suitable material in bone
tissue engineering should attract osteogenic elements (i.e., be
osteoinductive) and support tissue regeneration (i.e., be
osteoconductive). In recent years, numerous types of scaffold
materials and structures have been compared.62 Scaffolds can
be of a natural or a synthetic origin. Those of a natural origin
have the advantage of being biocompatible and bioactive,
whereas for synthetic ones it is possible to control the rate of
degradation, the microstructure, the porosity, and the
mechanical strength.63,64 An example of a natural polymer
is coral. The natural structure of coral has excellent mechani-
cal properties: in fact, it has an interconnected porousstructure that allows it to withstand compressive breaking
stress, and has good reabsorbability and biocompatibility. Its
three-dimensional structure, with the presence of intercon-
nected pores of around 260 mm in diameter, is similar to that of
spongy bone, encouraging the spread of the new bone
ingrowth. Recently, it has been shown that stem cells rapidly
move inside Biocoral cavities and later begin to differentiate
into osteoblasts.65 Examples of synthetic polymers are PLGA
and titanium, which possess high biocompatibility without
rejection and inflammatory reactions.62–65 Researchers have
also demonstrated66 that there is complete osteointegration
on a titanium surface. They have tested laser-sintered
titanium (LST) and acid-etched titanium surfaces with both
human osteoblasts and DPSCs. The LST surfaces induced
better and quicker differentiation of DPSCs into osteoblasts.66
Although an in vitro culture system offers a simplified
model to investigate differentiation ability, the potential of
this system for dental pulp tissue engineering needs to be
verified in vivo. In fact, potential development and formation of
an appropriate histological structure often cannot be fully
realized in vitro. Thus, studies on DPSC behaviour in vivo have
been conducted in animal models, implanting constructs
composed of cells seeded onto a wide variety of biomaterials,
including calcium phosphates, collagen hydroxyapatite, poly
(D,L) lactide-based materials, bioactive glasses, and methacry-
late-based biomaterials.56,66–70 These systems can generate
highly ordered collagenous matrix deposition and give rise to
bone containing vessels, fundamental for complete integra-
tion with the host.
It is important also to consider various animal models with
bone defects used for tissue engineering in bone regeneration.
Dog, mice or rats, pig, sheep, and rabbit are those more used in
this field. Unfortunately, there isn’t an ideal animal model.
Each model has advantages and/or disadvantages. Certainly,
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others71; mice and rats are the worst models due to their
dissimilarities in terms of size and bone structure compared to
humans.71 Despite this, many studies report that DPSCs form
bone in animal models in which cranial and mandibular bone
defects have been generated. Only one study has reported a
complete failure to form bone by DPSCs loaded on a porous
HA/TCP ceramic scaffold.72 However, to overcome the limita-
tions of ex vivo grown stem cell transplants, recent reports
have explored the recruitment of endogenous progenitor cells
as a novel strategy for in situ tissue regeneration.73 It has been
demonstrated that the interaction between the chemokine
SCF and its receptor c-Kit is a potent aid in the regeneration of
dental pulp and other mesenchymal tissues, and is capable of
inducing cell homing, angiogenesis, and tissue remodelling.73
In summary, DPSCs are an excellent model to study bone
formation on substrates appropriate for clinical bone-remo-
delling applications.61,74
4. Human grafts
The majority of studies evaluating in vivo applications of DPSCs
are performed on animal models. There have been few clinicalFig. 3 – (A) Representation of human mandible defect repair usi
showing a reabsorbed spongy bone in the control site (original m
grafting) at the test site, showing a compact bone (original magtrials. In one clinical study,75 bone formation subsequent to
DPSC transplantation was evidenced radiographically.
Researchers extracted cells from dental pulp of drawn third
molars and seeded them onto collagen scaffolds. The two
mandibular third molars of each patient were extracted
simultaneously; one side received a biomaterial construct
loaded with cells, and the other side, used as a negative control,
was filled with biomaterial alone. Three months after injury,
radiographical and histological analysis showed a noticeable
difference in bone regeneration between the two sites (Fig. 3):
the control side had a significantly lower amount of regenerated
bone.75 That study gave clear evidence of the possibility of
employing DPSCs to repair bone defect in humans. After three
years of follow-up,76 both stability and the characteristics of the
regenerated bone were examined by means of the novel
synchrotron radiation-based holotomography (HT) technique.
The use of histological methods and synchrotron radiation-
based HT showed that 3 years after surgery, the regenerated
bone was uniformly vascularized and qualitatively compact.
This result demonstrated that DPSCs successfully repair bone.
In this context, compact bone regenerated after DPSC engraft-
ments in the mandible could be considered of fundamental
importance to limit pathologic fracture and to guarantee better
quality of life in oral cancer patients.76 More clinical trials onng DPSCs. (B) Histological evaluation (3 years after grafting)
agnification 200T). (C) Histological evaluation (3 years after
nification 200T).
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for a regenerative therapeutic approach.
5. Realistic perspectives
New strategies are needed to fully develop the clinical
application potential of these studies. This should involve
both researchers/clinicians and improvements in good
manufacturing practice (GMP) procedures/rules. We must
think how to do more research that is focused towards clinical
application rather than the publication of articles without an
effective therapeutic prospect.
The GMP procedures that must be followed by researchers/
clinicians, even for the engraftment of autologous cells, are
not really orientated for research on humans. They are much
too difficult, too long, and extremely expensive, so much so
that often researchers and clinicians are discouraged to start
with a clinical trial application in the first place. The long
bureaucratic procedures, the continuous requests for the
tiniest of details within protocols, and the demand of fixed or
over-fixed steps, are not compatible with the clinical develop-
ment of stem-cell-based therapy. This type of procedure is
devoted to patients with differing needs, whose stem cells are
often unique in many features. This does not mean that a safe
protocol cannot be drawn up and used, but it must be a flexible
one. We believe and strongly suggest that only general rules
should be standardized, not everything. Importantly, this
would not have an effect on the safety of patients, but may
very well affect the results, which cannot be identical for all
patients due to physiological diversity in the biology of each
patient. We hope that the above will stimulate in a short time
the opening up of the possibility for advanced therapies that
enhance the well-being of patients in need.
Stem cell research has expanded at an exponential rate, but
its therapeutic applications have progressed much more
slowly. Despite this, stem cell therapy represents a fascinating
new approach for the management of disease. Worldwide
scientific advances using stem cells in therapeutic, recon-
structive, orthopaedic, and cosmetic applications are the
future of personalized and regenerative medicine. Stem cell
therapy allows the repair of defective tissues or functions
through the transplantation of live cells. However, immune
rejection is a major risk for cell transplantation, so biosecurity
is a crucial point for cell therapy, requiring control of cell
transformation and a protocol for cellular biobanking.
In the next few years, the targets of cell therapy will be to
identify and understand cell differentiation mechanisms, so
that optimal cell populations and culture conditions can be
used in a more efficient treatment of disease. A thorough
knowledge of stem cell physiology may enhance development
of novel and more competent therapeutic approaches and
fulfil the huge impact that stem cell therapy will have for
future healthcare. In parallel, it is important to evaluate the
role of specific and new molecules that recruit endogenous
stem cells for tissue regeneration. This strategy is hopefully an
easier way towards a clinically acceptable procedure, side-
stepping difficulties caused by bureaucracy and policy.
Therefore, we expect that increased application of stem cells
will strengthen the translatability to supporting clinical trials.6. Conclusions
DPSCs are mesenchymal stem cells expressing mesenchymal,
haematopoietic and stemness markers. These cells:
i. differentiate into different tissues of mesenchymal origin,
but also into functional melanocytes and neurons;
ii. maintain their characteristics after cryopreservation for
years if stored as selected stem cells and not as part of
whole pulp;
iii. differentiate into bone-like tissues in animal models when
loaded on scaffolds;
iv. regenerate bone in human grafts;
v. are an excellent model for the study of bone formation on
substrates appropriate for clinical bone remodelling
applications.
Unfortunately, clinical trials using DPSCs have not been
widely reported. However, the basic and clinical data reported
in this review should encourage the development of DPSC-
based procedures with practical applications for humans.
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